Rare disease (orphan) designations

  • Email
  • Help

This page allows you to find information on rare disease (orphan) designations based on applications that have been assessed by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP).

An orphan designation allows a pharmaceutical company to benefit from incentives from the European Union to develop a medicine for a rare disease, such as reduced fees and protection from competition once the medicine is placed on the market. Applications for orphan designation are examined by the COMP, which adopts an opinion that is forwarded to the European Commission. The European Commission then decides whether to grant an orphan designation for the medicine in question. 

For more information, see Medicines for rare diseases.

Document status

Include:

Browse by letter

Search for active substance by letter and/or number:

Search by keyword

Search for keyword:

Download results to spreadsheet
EPAR Search results
Active substance Disease / condition Date of decision Decision Medicine name

Recombinant hisitidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors

Treatment of follicular lymphoma 2004-12-23 Positive  

Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors

Treatment of diffuse large B-cell lymphoma 2009-07-24 Positive  

Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors

Treatment of mantle cell lymphoma 2004-12-20 Positive  

Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors

Treatment of multiple myeloma 2004-12-20 Positive  

Recombinant homodimer of the human annexin V

Prevention of ischaemia / reperfusion injury associated with solid-organ transplantation 2012-01-11 Withdrawn  

Recombinant human ADAMTS-13

Treatment of thrombotic thrombocytopenic purpura 2008-12-02 Positive  

Recombinant human C1-inhibitor

Prevention of delayed graft function after solid organ transplantation 2007-02-19 Positive  

Recombinant human C1-inhibitor

Treatment of angioedema caused by C1 inhibitor deficiency 2001-05-11 Withdrawn  

Recombinant human CXCL8 mutant

Prevention of delayed graft function after solid organ transplantation 2008-09-22 Positive  

Recombinant human IgG1 kappa light chain monoclonal antibody targeting plasma kallikrein

Treatment of hereditary angioedema 2015-10-09 Positive  

Recombinant human N-acetylgalactosamine-6-sulfatase

Treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome) 2009-07-24 Positive Vimizim

Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues

Treatment of glycogen storage disease type II (Pompe‚Äôs disease) 2016-08-29 Positive  

Recombinant human acid alpha-glucosidase

Treatment of glycogen storage disease type II (Pompe's disease) 2001-02-14 Expired Myozyme

Recombinant human acid ceramidase

Treatment of Farber disease 2014-02-19 Positive  

Recombinant human acid ceramidase

Treatment of cystic fibrosis 2015-08-10 Positive  

Recombinant human acid sphingomyelinase

Treatment of Niemann-Pick disease, type B 2001-09-19 Positive  

Recombinant human alkaline phosphatase

Treatment of hypophosphatasia 2015-01-15 Positive  

Recombinant human alpha 1 chain homotrimer of type VII collagen

Treatment of epidermolysis bullosa 2014-06-04 Positive  

Recombinant human alpha-1 antitrypsin

Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency 2002-04-30 Withdrawn  

Recombinant human alpha-1 antitrypsin

Treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency 2001-05-30 Withdrawn  

Recombinant human alpha-1-microglobulin

Treatment of pre eclampsia 2014-07-04 Positive  

Recombinant human alpha-Mannosidase

Treatment of alpha-mannosidosis 2005-01-26 Positive  

Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan

Treatment of glycogen storage disease type II (Pompe's disease) 2014-03-26 Positive  

Recombinant human anti-interferon gamma monoclonal antibody

Treatment of haemophagocytic lymphohistiocytosis 2010-06-09 Positive  

Recombinant human apolipoprotein A-I in a complex with phospholipids

Treatment of ATP-binding cassette transporter A1 deficiency 2014-08-22 Positive